Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring

Nisha Kundu BDS, MSc (CosMed), MSc (IHM) | Rohit Kothari MD | Nimish Shah MBBCh, MRCGP, DRCOG | Sunmeet Sandhu MD, DNB | Durga Madhab Tripathy MD, DNB | Hassan Galadari MD | Michael H. Gold MD | Mitchel P. Goldman MD | Martin Kassir MD | Hadrian Schepler MD | Stephan Grabbe MD | Mohamad Goldust MD

1Imperial College, London, UK | 2Dermatology, Command Hospital Air Force, Bengaluru, India | 3Cardiff University, Cardiff, UK | 4University of South Wales, Pontypridd, UK | 5Dermatology, 7 Air Force Hospital, Kanpur, India | 6Dermatology, Military Hospital, Agra, India | 7College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE | 8Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, Tennessee, USA | 9Cosmetic Laser Dermatology: A West Dermatology Company, San Diego, California, USA | 10Department of Dermatology, University of California, San Diego, California, USA | 11Worldwide Laser Institute, Dallas, Texas, USA | 12Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

Abstract

Background: Masseter muscle hypertrophy (MMH) usually presents with cosmetic concerns as it may lead to widening of the lower face. Apart from the traditional surgical approaches, botulinum toxin type A (BTA) injection is a non-invasive treatment option available. There are no standard guidelines for this procedure.

Objectives: To study the efficacy of botulinum toxin A in MMH for lower face contouring.

Methodology: The Cochrane Library, PubMed/MEDLINE, Google-scholar, ScienceDirect database, and ResearchGate from inception until September 2021 were searched using the keywords "botulinum toxin type A," "masseter muscle hypertrophy," "lower face contouring," and "masseter botox." All available retrospective and prospective studies, case-series, case-reports, and expert reviews were included with an emphasis on efficacy of BTA in MMH and units injected into the muscle, points of placement, adverse events, and the duration of its effect. Reference lists of the resultant articles, as well as relevant reviews, were also searched.

Result: 40 articles were shortlisted for the review, of which 14 studies with sample-size ≥10 in accordance with the study requirements were summarized in a tabular form for analysis and easy comparison and reference.

Conclusion: BTA injection is a non-invasive, safe, and effective treatment for MMH. The optimum number of BTA units could not be ascertained due to wide variability in the studies as well as ethnicity of patients and extent or some measurement of MMH. The points of placement of injection should be well within the boundaries of the masseter muscle. The maximum effect of BTA after a single injection session is usually seen in ~3 months, and the duration may last for 6–12 months. Multiple injection
However, the nerve terminals start to regenerate in the muscle, causing a temporary flaccid paralysis of the muscle. Acetylcholine, released from the nerve terminals, inhibits the release of acetylcholine at the neuromuscular junction, causing a temporary flaccid paralysis.

 sessions may be required to maintain a long-term effect. Injection technique and total number of injection units of neuromodulator must be individualized for each patient.

KEYWORDS
Botulinum toxin type A, lower face contouring, masseter botox, masseter muscle, masseter muscle hypertrophy

1 | INTRODUCTION

Sculpted high cheekbones with hollowness under them, giving a triangular or heart shaped female face is considered the most aesthetic ideal one. Usually, Asians have wider face with high malar prominence and a squared jawline. Smaller and slimmer faces with a triangular shape are considered more beautiful and attractive by many and are more desirable amongst women as compared with men. In males, wide and square shape jawline is considered more attractive and masculine.

The masseter muscle is one of the of mastication muscles which helps mainly in biting and chewing of food. Hence, the volume and width of this muscle is determined especially by the biting force, chewing habits, the type of food, diet, or habits such as teeth clenching, bruxism, or any other temporo-mandibular joint (TMJ) disorder. Any of these can lead to masseter muscle hypertrophy (MMH), which gives a squarish appearance to the face or jawline.

Surgical resection of the mandibular bone or masseter muscle or liposuction of the subcutaneous fat was performed historically as a treatment. A more recent non-surgical treatment option includes botulinum toxin injections into the muscle to reduce its size. Type A Botulinum toxin (BTA) was first used to correct masseter hypertrophy in 1994. When the toxin is injected into the muscle, it inhibits the release of acetylcholine at the neuromuscular junction, causing a temporary flaccid paralysis of the muscle. However, the nerve terminals start to regenerate in ~3 months, and hence, it requires repeated sessions to maintain complete paralysis. Temporary atrophy of the muscle due to its chemodenervation effect is noted and persists for 3~6 months. Various side-effects associated with the procedure have been reported and are most likely secondary to excessive infiltration or inaccurate placement of the neuromodulator. These consist of smile limitation or asymmetry, reduced chewing force, problem in wide mouth opening, bruising, incipient jowl and skin sagging, local pain at the site of injection, mild headache, awkward facial expressions, speech disturbances, uneven bulging of muscles, sunken cheeks, and herniation of the parotid gland through the attenuated overlying muscle.

There are no available standard guidelines for this procedure. This review aims to provide an overview of efficacy of BTA in MMH and the optimum units injected into each side of masseter muscle, points of placement of injection, adverse events, and the duration of its effects.

2 | METHODOLOGY

The Cochrane Library, PubMed/MEDLINE, Google scholar, Science Direct database and ResearchGate from inception until September 2021 were searched using the keywords “botulinum toxin type A,” “masseter muscle hypertrophy,” “lower face contouring,” and “masseter botox.” All available retrospective and prospective studies, case-series, case-reports, and expert reviews were included with an emphasis on efficacy of BTA in MMH and units injected into the muscle, points of placement, adverse events, and the duration of its effect. The observations were analyzed to find the best possible dose of BTA and the location of points of injections to achieve the most desirable esthetic contouring of lower face. 40 articles were shortlisted for the review, of which 14 studies with sample-size ≥10 in accordance with the study requirements were summarized in a tabular form for analysis and easy comparison and reference.

3 | LOWER FACE AESTHETICS

Triangular shaped lower face with a perfect jawline is the most desirable shape among females as compared to a broad squarish lower face, which is considered more attractive in males for many people. In many Asian cultures small, slim and oval faces are known to bring good fortune, and hence, there is more interest to achieve this. The aesthetics of lower face are determined by three main factors:

- Size of the bony mandible
- Mass of the masseter muscle
- Volume of subcutaneous fat tissue

The size and shape of the mandible is predetermined at the time of birth and is fixed by the time of adulthood. It also varies between different ethnicities and races. The volume of subcutaneous fat varies from person to person depending on the individual body mass index. In addition, it is found that different ethnicities have variations in thickness of facial fat pads.

4 | MASSETER MUSCLE HYPERTROPHY

Masseter is one of the four muscles of mastication in the maxillo-facial region. It is a quadrangular muscle, which is divided into superficial and deep portion. The superficial portion arises from thick
aponeurosis on the zygomatic bone and the anterior two thirds of zygomatic arch and the deep portion arises from zygomatic arch and is covered anteriorly by the deep fibers and posteriorly by the parotid gland. Masseter muscle contractions help in elevation and protrusion of the mandible. The first known case report of MMH dates back to 1880 in a 10-year-old girl reported by Legg JW.11 Benign or idiopathic MMH is a relatively uncommon condition, with unilateral or bilateral enlargement of the muscle. Patients are usually asymptomatic and seek advice only when they notice aesthetic concerns due to asymmetry of lower face.12 The most common reasons leading to masseter hypertrophy can be dietary habits, chewing gums, bruxism, and TMJ disorders, which may be stress induced. As per Teixeira, masseter hypertrophy can be classified as congenital and acquired, that is, functional hypertrophy.12 Masseter hypertrophy should be accurately diagnosed and differentiated from similar looking conditions such as parotid or masseter tumor, inflammatory parotid disease, salivary gland disease, and masseter intrinsic myopathy.

Most patients usually present with increase width or dimensions of the lower face also termed as "square face." The associated symptoms can be pain in the TMJ, headache, muscular stress, or trismus. The diagnosis of MMH is established by clinical examination and palpation of the muscle. The palpation of the muscle carried out in both contracted as well as relaxed state helps in pin pointing the location of hypertrophy. Ultrasonography (USG), magnetic resonance (MR) images help to detect the enlarged muscle. Computed tomography (CT) scans and panoramic radiographs may be used to observe any reactive bone formation in the mandible.13

### 5 | TREATMENT MODALITIES FOR MMH

The treatment of MMH largely depends on the underlying cause. If its stress induced, then psychological endorsement is essential. Mouth guard, antispasmodics, and/or analgesics can be used as well. Surgical resection of the masseter muscle through a submandibular incision was first proposed by Gurney in 1947 and later by Beckers who used an intraoral approach to avoid facial nerve injury and facial scarring.15

The commonly used surgical technique for MMH is an extraoral approach, following a submandibular incision, avoiding the mandibular nerve.12 With bony hyperplasia, reduction osteoplasty is preferred. The possibility of post-operative complications such as facial nerve paralysis, hematoma formation, trismus, infection, and other general anesthesia-related complications is rare. The use of radiofrequency energy to reduce the size of muscle is claimed to be long lasting with less side effects as compared with surgical procedures.16 The least invasive and most widely used modality is BTA. It was first used by Smyth, Moore, and Wood in 1994.17,18 BTA treatment helps in decreasing the muscle bulk, which also reshapes the lower face along with improving pain, grinding, and clenching symptoms. Adverse effects are minimal and short lasting.19

### 6 | PATIENT SELECTION

Contouring of the lower face is a cosmetic procedure, and hence, patient selection is important. Patients over 40 years with sagging face and jowls are not ideal candidates, as loss of muscle volume will enhance incipient jowl. Patients with very high cheekbones also need to be counselled as the results may further accentuate the appearance of cheekbones.1 Those with excess fatty tissue on the face may not appreciate the difference after the reduction of masseter muscle; therefore, other means of fat reduction such as liposuction or injection with deoxycholate should be considered.2 Patients with other medical or psychological conditions like bruxism or stress may need other therapies as previously described.20 Ideal patients for this procedure are between 16 and 50 years with broad or square shaped lower face due to overdeveloped masseter with realistic expectations.2

### 7 | INJECTION TECHNIQUES

Various techniques for injecting BTA into the masseter muscle are demonstrated in Figure 1 and summarized in Table 1. Moore, Woode, and Smyth first published on this procedure.17,18 Kim HJ et al uses two injection points marked on a line from tragus to corner of mouth 1 cm apart. Another two injection points are given 1cm above and below this reference line.21 The 3-point injection technique involves one point inferior to tragus-mouth line at the thickest point of muscle and two points 1cm away from the anterior and posterior borders of masseter. This helps to reduce the chances of affecting the risorius muscle or causing a herniation of the parotid gland.22 5-point injection technique involving the most bulging points is another method.23 Two points of injections, one at angle of mandible, and other one in the region of zygomatic arch was used by Lindern et al.24 A 2-point injection technique in the lower one third of muscle 1 cm apart may also be used.25,26 Some authors prefer lower outer quarter of muscle for injecting after marking the anterior and posterior margin of masseter, earlobe to mouth corner line, and border of mandible and dividing the muscle into four equal parts.27 A more recent technique uses ultrasound guided injections at 2-4 points, 1.5cms apart within the borders of the muscle and tragus-mouth line.28 The most important concept while injecting masseter with BTX is to remain well within the boundaries of the muscle to avoid complications most commonly asymmetry.

### 8 | DOSAGE, FREQUENCY, AND EFFICACY

Various dosage regimens and frequency of injecting BTA are summarized in Table 2. The first case report of treating MMH by Moore and Woode (1994) utilized 300 units of BTA in a 30-year-old Caucasian male with stress-related TMJ dysfunction arthropathy, myofascial pain syndrome, and masseter hypertrophy. 2-weeks after injection, slight reduction in volume of muscle was noted.
which lasted for ~6 months without any side-effects.\textsuperscript{18} Multiple studies using much lower dosages have since been reported with a variable success rate. One of the largest studies by Kim NH et al involved 1021 patients treated with 100–140 units of abobotulinumtoxin A (ABO) for lower face contouring (383 patients could be followed up for >3 months). Thickness reduced by 31% and maximum reduction in muscle strength was seen after 10–12 weeks and 50% required a second injection after 4–7 months. Biopsy of muscle tissue four months after the procedure revealed atrophy, necrosis, and hyaline degeneration.\textsuperscript{2} Xie et al.\textsuperscript{29} (2014) used a lower dose (20–40 units) onabotulinumtoxin A (ONA) in 220 patients with MMH. Maximum effect was observed at 3 months, with reduction in muscle thickness from 12.9 ± 2.9 to 8.7 ± 1.7 mm in 40 patients who could be followed-up till four months. They observed 60% of complications in those who had received higher dosage of BTA. Maximized masticatory movement for more than 2 h/day post masseter-BTA may result in longer lasting results may be up to 1 year even with lower dosage of BTX.\textsuperscript{27} Frequent BTA or Xeomin [incobotulinumtoxin A (INCO)] injections given at intervals of 3–6 months may be effective in long term management of masseter hypertrophy and contouring of lower face.\textsuperscript{30,31} Prabotulinumtoxin A (PRA) in a dosage of 48–72 units followed by reinjection after 12-weeks is also effective in a dose-dependent manner; however, higher doses may lead to discomfort during jaw movement.\textsuperscript{32} It is important to note that studies which reported on the use of higher doses of BTA are almost always from Asian countries, especially Korea. Our experience is that Caucasian patients achieve acceptable results using 15–30 units per side (Figures 2, 3).

USG can observe the deep inferior tendon of masseter muscle which may reduce the side-effects of masseteric bulging when applying dual-plane or retrograde injection methods.\textsuperscript{33} In the quest of searching for a safer and more efficient injecting technique, Bae H et al. concluded that USG-guided method is better than a blind procedure due to direct visualization of the muscle and may prevent paradoxical masseteric bulging that may occur during the blind injection.\textsuperscript{34} Botulinum toxin type A may even be combined with other therapies such as autologous fat grafting for masseter hypertrophy and wide faces with very few complications and rapid recovery.\textsuperscript{35}

**FIGURE 1** Injection points for masseter botox
As with any other treatment modality, BTA injection also carries a risk of various side-effects albeit mild and manageable in most cases. ~50% patients may experience these effects with muscle weakness, reduced crunching power, or reduced bite force being the most commonly reported, especially in Asian patients treated with dosages >30 units/side. Kim & colleagues observed these side effects in 192/383 participants. These were temporary and usually resolved within a period of 1–2 months. Another study by Wei et al reported bite weakness and muscle fatigue in 44/98 patients. Diffusion of BTA into the surrounding musculature such as the zygomaticus or buccinator can cause changes in facial expressions or facial asymmetry. To avoid this, BTA should be injected well within the boundaries of the masseter muscle and superiorly a line joining the tragus to oral commissure should be considered as the upper margin.

MMH treatment may at times lead to temporal fossa volume increase, which may be secondary to masseter paralysis or a transient bulge in the muscle, which may be secondary to minor bleeding.

**TABLE 1 Various injection techniques of masseter Botox**

| S. No. | Study | Injection technique |
|--------|-------|---------------------|
| 1      | Moore & Wood et al (1994) | Injected at the most prominent point in the masseter muscle |
| 2      | Smyth AG et al (1994) | Marked two points for the injection; first point was at the most prominent point upon clenching the teeth and second point, 1-2cm above the first one |
| 3      | Mandel & Tharakan et al (1999) | 5 points of injection at most bulging points of the masseter muscle |
| 4      | Lindern J.J et al (2001) | Gave another technique for injecting BTA into the masseter muscle. Two points of injections, one at the angle of mandible and other one in the region of zygomatic arch was used |
| 5      | Kim H. J, Yum KW et al (2003) | A line is drawn from tagus to the corner of mouth and two injection points are marked on this line 1cm apart. Another two injection points are given 1cm above and below this reference line (Figure 1A) |
| 6      | Kim N.H et al (2005) | Multiple injections given at 3–4 points, 1.5cm above the mandibular angle (Figure 1C) |
| 7      | Chang CS et al (2007) | Establishing the area of injection by marking the anterior and posterior margins of masseter, inferior margin of zygomatic arch and border of mandible and then dividing the area into six equal sized grids to inject BTA 1cm apart (Figure 1D) |
| 8      | Kim NH, Park RH et al (2010) | A safety zone can be established by marking the boundaries of the masseter muscle, anteriorly and posteriorly by borders of the muscle, superiorly by earlobe-mouth corner line, inferiorly by mandibular border. 50% of BTA is injected into the centre of the safety zone and 25% is given at two other points within the safety zone (Figure 1B) |
| 9      | Shim et al (2010) | 2-point injection technique in lower one third of the masseter muscle 1 cm apart |
| 10     | Cha YR et al (2013) | 2 points of injection 1cm apart in lower third of the muscle at the points of maximum prominence |
| 11     | Bae J.H et al (2014) | Three point injection technique: One point inferior to the tragus-mouth line at the thickest point of the muscle, and two points 1 cm away from the anterior and posterior borders of the masseter muscle are marked for injection. This helps to reduce the chances of affecting the risorius muscle (Figure 1E) |
| 12     | Wei J et al (2015) | Marked anterior and posterior margin of masseter, earlobe to mouth corner line, border of mandible and divided the muscle into four equal parts. The injection of BTA was given in the lower outer quarter of the muscle |
| 13     | Quezada-Gaon et al (2016) | Suggested an ultrasound guided injection technique at 2–4 points, 1.5 cm apart within the borders of the muscle and tragus-mouth line |
| 14     | Hong JY et al (2021) | An imaginary line linking the tragus and mouth corner was used to mark a safe injection zone. Needle tip was inserted until it reached the mandible and then retracted 1–2 mm to avoid injection into superficial facial musculature. 0.72 ml of the test solution at each side using the 3-point injection technique below the drawn line |

**SIDE EFFECTS**

As with any other treatment modality, BTA injection also carries a risk of various side-effects albeit mild and manageable in most cases. ~50% patients may experience these effects with muscle weakness, reduced crunching power, or reduced bite force being the most commonly reported, especially in Asian patients treated with dosages >30 units/side. Kim & colleagues observed these side effects in 192/383 participants. These were temporary and usually resolved within a period of 1–2 months. Another study by Wei et al reported bite weakness and muscle fatigue in 44/98 patients. Diffusion of BTA into the surrounding musculature such as the zygomaticus or buccinator can cause changes in facial expressions or facial asymmetry. To avoid this, BTA should be injected well within the boundaries of the masseter muscle and superiorly a line joining the tragus to oral commissure should be considered as the upper margin. MMH treatment may at times lead to temporal fossa volume increase, which may be secondary to masseter paralysis or a transient bulge in the muscle, which may be secondary to minor bleeding.

**CONCLUSION**

BTA injection is a non-invasive, safe, and effective treatment for MMH. The optimum number of BTA units could not be ascertained due to wide variability in the studies as well as ethnicity of patients and extent or some measurement of MMH. The points of placement of injection should be well within the boundaries of the masseter muscle. The maximum effect of BTA after a single injection session is usually seen in ~3 months and the duration may last for
TABLE 2 Summary of studies on masseter botox (n ≥ 10)

| Study No. | Study | Sample Size | Type of BTA | Units injected | Methods of assessment |
|-----------|-------|-------------|-------------|-----------------|-----------------------|
| 1.        | Park, Ahn et al (2003) | 45 | ONA | 25–30 | USG, CT, Patient satisfaction |
| 2.        | Kim et al (2003) | 11 | ONA | 30 | CT, clinical photographs |
| 3.        | Kim, Chung et al (2005) | 383 | ABO | 100–140 | USG, Clinical photographs |
| 4.        | Choe SW et al (2005) | 22 | ONA | 10–30 | USG, clinical photographs, Patient satisfaction scores |
| 5.        | Kim JH et al (2007) | 32 | ONA | 25–35 | CT, EMG |
| 6.        | Liew & Dart et al (2008) | 34 48 | ONA | 25–30, 40–45 | Clinical photographs, Patient feedback |
| 7.        | Shim et al (2010) | 15 | ONA | 25 | 3D Laser Scan |
| 8.        | Cha YR et al (2013) | 10 | ONA | 25 | 3D Laser scan |
| 9.        | Klein et al (2014) | 10 | ABO | 90 | Clinical photographs |
| 10.       | Xie Y et al (2014) | 40 | ONA | 20–40 | USG, Clinical photographs |
| 11.       | Wei et al (2015) | 98 | ONA | 35 | USG, CT |
| 12.       | Shome, D, Khare S et al (2019) | 50 | ONA | 30 | USG, Clinical photographs |
| 13.       | Shome, D, Vadera S, et al (2020) | 30 | INCO | 30 | USG, Clinical photographs |
| 14.       | Hong JY et al (2021) | 90 | PRA | 24–96 | USG, Clinical photographs, 3D imaging |

Note: Conversion factor for various botulinumtoxin A is ONA: INCO: ABO: PRA=1:1:2.5:1.
Abbreviations: ABO, Abobotulinumtoxin A; INCO, Incobotulinumtoxin A; ONA, Onabotulinumtoxin A; PRA, Prabotulinumtoxin A.
| Results                                                                 | Side effects                                           | Follow-UP | Maximum effect | Duration of effect |
|------------------------------------------------------------------------|-------------------------------------------------------|-----------|----------------|-------------------|
| Reduced muscle thickness by 19.5%, improved satisfaction              | Masticatory difficulty, Muscle ache                   | 10 months | 3 months       | 10 months         |
| Reduced muscle volume by 35.4%                                        | Masticatory difficulty, Altered Facial expressions, Sunken cheeks | 6 months  | 3 months       | 6 months (50%)    |
| Reduced muscle thickness by 31%                                        | Reduced crunching power, Bulging of muscle, Facial asymmetry | 24 months | 3 months       | 7 months (50%)    |
| 25% reduced muscle thickness, improved score                           | Pain at injection site, Headache                      | 9 months  | 4 months       | 9 months          |
| 27.5% reduced muscle thickness and cross-section, Reduced EMG values   | Muscle weakness, pain at injection site, headache     | 3 months  | 3 months       | -                |
| Aesthetic & functional improvement, 30% volume reduction               | Muscle bulge, asymmetry                               | 10–24 months | 2–3 months | 9–12 months |
| Reduced volume & width of lower face                                   | No side effects                                       | 6 months  | 3 months       | 6 months          |
| Decreased volume and thickness of lower face                           | Not side effects                                      | 3 months  | 3 months       | -                |
| Reduction in lower face width                                          | Smile limitation, Smile asymmetry, Masticatory fatigue | 6 months  | 3 months       | -                |
| Reduction in muscle thickness by 33%                                   | Dizziness, headache, smile limitation, disappearance of dimple | 4 months  | 3 months       | -                |
| Reduced muscle volume by 30.5%                                        | Bite weakness, Headache, bruise                       | 15 months | 3 months       | 6–12 months       |
| Reduced volume by 12%                                                  | Pain at injection site, Headache                      | 4 Years   | 3 months       | -                |
| Reduced volume by 26.85% (02 injection) & 43.42% (03 injection)       | Mild pain at injection site                           | 2 Years   | 6 Months       | 12–24 months      |
| 11.51±1.13% mm to 20.53± 8.37% at 12 weeks with 96 units              | Transient masseter muscle pain                        | 4 months  | 3 months       | 3–4 months        |

6–12 months. Multiple injection sessions may be required to maintain a long-term effect. Injection technique and total number of injection units of neuromodulator must be individualized for each patient.

**ACKNOWLEDGMENTS**

Open access funding enabled and organized by ProjektDEAL.

**CONFLICT OF INTEREST**

None.

**AUTHOR CONTRIBUTIONS**

Nisha Kundra contributed in writing and revising the manuscript. Rohit Kothari, Nimiram Shah, Sunmeet Sandhu, Durga Madhab Tripathy, Hassan Galadari, Michael H. Gold, Stephan Grabbe, Hadrian Schepler, Martin Kassir, Mitchel P Goldman involved in review and revising the manuscript. Mohamad Goldust involved in conception, writing, review, and revising the manuscript.

**ETHICAL APPROVAL**

This was a review article and needs no ethical approval. Written consent was obtained from the patients regarding their pictures.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**

Rohit Kothari [https://orcid.org/0000-0002-9875-2563](https://orcid.org/0000-0002-9875-2563)

Hassan Galadari [https://orcid.org/0000-0001-8223-2769](https://orcid.org/0000-0001-8223-2769)

Michael H. Gold [https://orcid.org/0000-0002-5183-5433](https://orcid.org/0000-0002-5183-5433)

Mohamad Goldust [https://orcid.org/0000-0002-8646-1179](https://orcid.org/0000-0002-8646-1179)

**REFERENCES**

1. Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in East Asians. Dermatol Surg. 2019;45:566-572.
2. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115:919-930.
3. Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodelling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014;89:878-884.
4. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003;29:477-483.
5. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55:8.
6. Chang CS, Bergeron L, Yu CC, Chen PK, Chen YR. Mandible changes evaluated by computed tomography following Botulinum
Toxin A injections in square-faced patients. Aesthetic Plast Surg. 2011;35:452-455.

7. Wu WT. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width. Facial Plast Surg Clin North Am. 2010;18:133-140.

8. Peng H-LP. Hypertrophy M. Toxin treatment techniques, causes of complications, and prevention. Botulinum Toxin. 2018;1:73-81.

9. Vashi NA, de Castro Maymone MB, Kundu RV. Aging differences in ethnic skin. J Clin Aesthet Dermatol. 2016;9:31-38.

10. Corcoran NM, Goldman EM. Anatomy, head and neck, masseter muscle. In: StatPearls [Internet]. StatPearls Publishing; 2022.

11. Legg JW. Enlargement of the temporal and masseter muscles on both sides. Trans Pathol Soc Lond. 1880;3:361-366.

12. Rispoli DZ, Camargo PM, Pires JL Jr, Fonseca VR, Mandelli KK, Pereira MA. Benign masseter muscle hypertrophy. Braz J Oral Maxillofac. 2008;74:790-793.

13. Ayyan M, Isler SC, Kasapoglu C. Combination of medical and surgical treatments for masseter hypertrophy. Case Rep Dentist. 2018;2018:1-5.

14. Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscle. Am J Surg. 1947;73:137.

15. Beckers HL. Masseteric muscle hypertrophy and its intraoral surgical correction. J Maxillofac Surg. 1977;5:28-35.

16. Ham JW. Masseter muscle reduction procedure with radiofrequency coagulation. J Oral Maxillofac Surg. 2009;67:457-463.

17. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg. 1994;32:29-33.

18. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 1994;32:26-28.

19. Almukhtar RM, Fabi SG. The masseter muscle and its role in facial contouring, aging, and quality of life: a literature review. Plast Reconstr Surg. 2019;143:39e-48e.

20. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125:1693-1705.

21. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29:484-489.

22. Bae JH, Choi DY, Lee JG, Seo KK, Tansatit T, Kim HJ. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg. 2014;40:1334-1339.

23. Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral Maxillofac Surg. 1999;57:1017-1019.

24. Von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107:327-332.

25. Cha YR, Kim YG, Kim JH, Kim ST. Effect of unilateral injection of botulinum toxin on lower facial asymmetry as evaluated using three-dimensional laser scanning. Dermatol Surg. 2013;39:900-906.

26. Shim WH, Yoon SH, Park JH, Choi Y-C, Kim ST. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan. Dermatol Surg. 2010;36:2161-2166.

27. Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type A injection. Dermatol Surg. 2015;41:1-10.

28. Quezada-Gaon N, Wortsman X, Peñaloza O, Carrasco JE. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol. 2016;15:238-244.

29. Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134:209e-e218.

30. Shome D, Khare S, Kapoor R. Efficacy of botulinum toxin in treating Asian Indian patients with masseter hypertrophy: a 4-year follow-up study. Plast Reconstr Surg. 2019;144:390e-e396.

31. Shome D, Vadera S, Shiva Ram M, Kapoor R. Efficacy of Incobotulinum toxin-A for the treatment of masseter muscle hypertrophy in Asian Indian patients: a 2-year follow-up study. J Cosmet Dermatol. 2020;19:1892-1899.

32. Hong JY, Jeong GJ, Kwon TR, Kim JH, Li K, Kim BJ. Efficacy and safety of a novel botulinum toxin a for masseter reduction: a randomized, double-blind, placebo-controlled, optimal dose-finding study. Dermatol Surg. 2021;47:e5-9.

33. Lee HJ, Jung SJ, Kim ST, Kim HJ. Ultrasonographic considerations for safe and efficient botulinum neurotoxin injection in masseteric hypertrophy. Toxins. 2021:13:28.

34. Bae H, Kim J, Seo KK, Hu KS, Kim ST, Kim HJ. Comparison between conventional blind injections and ultrasound-guided injections of botulinum toxin type A into the masseter: a clinical trial. Toxins. 2020;12:588.

35. Zheng Z, Hao Y, Yin J, Lei X, Cheng B, Huang W. Autogenous fat transplantation and botulinum toxin injection into the masseter muscle to create an ideal oval face. Aesthet Surg J. 2021;41(6):NP579-NP588.

36. Nikolis A, Enright KM, Rudolph C, Cotofana S. Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A. J Cosmet Dermatol. 2020;19:1294-1300.

37. Liew S, Dart A. Non-surgical reshaping of the lower face. Aesthet Surg J. 2008;28:251-257.

38. Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31:502-507.

39. Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type A evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119:711-717.

How to cite this article: Kundu N, Kothari R, Shah N, et al. Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring. J Cosmet Dermatol. 2022;21:1849–1856. doi:10.1111/jocd.14858